Header
For Healthcare Professionals
patient-profile-ketan

IN THE TREATMENT OF PATIENTS WITH CKD WITH OR WITHOUT  T2D*

HELP PROTECT KETAN’S KIDNEYS AND HEART

Prescribe JARDIANCE today to reduce his kidney disease progression or risk of CV death1

Ketan-55 1
Ketan-55 1

IN THE TREATMENT OF PATIENTS WITH CKD WITH OR WITHOUT T2D*

JARDIANCE REDUCED KIDNEY DISEASE PROGRESSION OR RISK OF CV DEATH†1,2

Ketan-28 1
Ketan-28 1
K-&-H

Protect the kidneys and heart across your broad range of patients with CKD2:

  • With and without T2D

  • With or without background use of RASi

FOR PATIENTS WITH TYPE 2 DIABETES AND CV DISEASE

IN EMPA-REG OUTCOME STUDY, JARDIANCE RESULTED IN A SIGNIFICANTLY LOWER RISK OF ALL-CAUSE MORTALITY COMPARED WITH PLACEBO1,3

Ketan-32b 1
Ketan-32b 1

Results from the EMPA-REG OUTCOME® trial.

  • *
    Adult patients with eGFR ≥45 to <90 mL/min/1.73 m2 with UACR ≥200 mg/g, or eGFR ≥30 to <45 mL/min/1.73 m2.
  • †
    In the EMPA-KIDNEY trial, a randomised, parallel-group, double-blind, placebo-controlled study of 6609 patients with CKD, the efficacy and safety of JARDIANCE 10 mg (n=3304) were evaluated vs placebo (n=3305). The primary endpoint in the EMPA-KIDNEY trial was a composite of CV death or progression of kidney disease (defined as end-stage kidney disease; the initiation of maintenance dialysis or receipt of a kidney transplant). Patients treated with JARDIANCE experienced a 28% RRR in this endpoint (HR=0.72; 95% CI: 0.64, 0.82; p<0.001).2
  • ‡
    ARR for the primary composite outcome of the kidney disease progression or CV death is 3.6% per patient-year at risk. Figure adapted from Herrington et al.2  
  • §
    NNT : 28 (95% Cl: 19, 53) per 2 year at risk.2
  • ll
    Standard of care: All patients received a RAASi unless an investigator judged that a RAASi was not indicated or tolerated.2
  • EMPA-REG OUTCOME study design: A randomized, double-blind, parallel-group trial comparing the risk of experiencing a major adverse cardiovascular event between Jardiance® (empagliflozin) tablets and placebo when these were added to and used concomitantly with standard-of-care treatments for type 2 diabetes and cardiovascular disease. A total of 7020 patients  were treated (JARDIANCE 10 mg [n=2345]; JARDIANCE 25 mg [n=2342]; placebo [n=2333]) and followed for a median of 3.1 years. All patients had established atherosclerotic cardiovascular disease at baseline, including one or more of the following:  a documented history of coronary artery disease, peripheral artery disease, myocardial infarction, or stroke. The primary  outcome was a reduction in the risk of cardiovascular events, defined by the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.3
  • ARR=absolute risk reduction; CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HR=hazard ratio; NNT=number needed to treat; RAASi=renin-angiotensin-aldosterone system inhibitor; RRR=relative risk reduction; T2D=type 2 diabetes; uACR=urinary albumin-to-creatinine ratio. 

  1. "Jardiance prescribing information; version 18th Jul 2024; Boehringer Ingelheim India.“

  2. Herrington WG, Staplin N, Wanner C, et al. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. (EMPA-KIDNEY results and the publication’s Supplementary Appendix.)

  3. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

IN THE TREATMENT OF PATIENTS WITH CKD WITH OR WITHOUT  T2D*

JARDIANCE DEMONSTRATES CONSISTENT KIDNEY AND CV EFFICACY OUTCOMES ACROSS THE BROADEST SPECTRUM OF SUBGROUPS†1

Ketan-pg-14a 1
Ketan-pg-14a 1
K-&-H

JARDIANCE is appropriate for a broad CKD patient population* you see every day in your practice

  • *
    Adult patients with an eGFR ≥45 to <90 mL/min/1.73 m2 with UACR ≥200 mg/g, or eGFR ≥30 to <45 mL/min/1.73 m2.1
  • †
    In the EMPA-KIDNEY trial, a randomised, parallel-group, double-blind, placebo-controlled study of 6609 patients with CKD, the efficacy and safety of JARDIANCE 10 mg (n=3304) were evaluated vs placebo (n=3305). The primary endpoint in the EMPA-KIDNEY trial was a composite of CV death or progression of kidney disease (defined as end-stage kidney disease; the initiation of maintenance dialysis or receipt of a kidney transplant). Patients treated with JARDIANCE experienced a 28% RRR in this endpoint (HR=0.72; 95% CI: 0.64, 0.82; p<0.001).1
  • ‡
    History of diabetes was defined as a patient-reported history of diabetes of any type, use of glucose-lowering medication, or a glycated haemoglobin level of at least 48 mmol per mole (6.5%) at the randomisation visit. More than 95% of patients with diabetes had type 2.1
  • §
    Values represent the measurement recorded at the randomisation visit or the most recent local laboratory result recorded before randomisation.1
  • CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HR=hazard ratio; RASi=renin-angiotensin system inhibitor; RRR=relative risk reduction; T2D=type 2 diabetes; uACR=urine albumin-to-creatinine ratio.

  1. Herrington WG, Staplin N, Wanner C, et al. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. (EMPA-KIDNEY results and the publication’s Supplementary Appendix.)

IN THE TREATMENT OF PATIENTS WITH CKD WITH OR WITHOUT  T2D*

JARDIANCE PROTECTS THE KIDNEYS BY SLOWING THE DECLINE IN RENAL FUNCTION OVER TIME†‡1

Ketan-2x-a
Ketan-2x-a
Kidney
By slowing the decline, JARDIANCE may
prolong better kidney function vs standard of
care#

IN THE TREATMENT OF PATIENTS WITH CKD WITH OR WITHOUT  T2D*

PRESCRIBE JARDIANCE AS FOUNDATIONAL AND BROAD TREATMENT TO HELP PROTECT THE KIDNEYS AND THE HEART1,2

Ketan-pg-48 (1)
Ketan-pg-48 (1)